Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn, a small-cap pharmaceutical company, has faced significant challenges, experiencing a notable decline and reaching a new 52-week low. The stock has underperformed its sector and has seen substantial losses over the past month, highlighting ongoing difficulties in the market.

Gujarat Themis Biosyn, a small-cap pharmaceutical company, has faced significant volatility, hitting a new 52-week low. The stock has declined 22.27% over four days and is trading below all major moving averages. Over the past year, it has underperformed compared to the Sensex, which has seen gains.

Gujarat Themis Biosyn, a small-cap pharmaceutical company, has faced notable stock volatility, experiencing a decline over three consecutive days. The stock has dropped significantly in the past month, underperforming compared to broader market indices, and is currently trading below key moving averages, indicating ongoing bearish sentiment.

Gujarat Themis Biosyn has announced its financial results for the quarter ending December 2024, revealing stable performance and an adjustment in its evaluation score. This change reflects a revised perspective on the company's financial standing as it continues to navigate the pharmaceuticals sector's complexities.

Gujarat Themis Biosyn's stock has faced notable declines, dropping for four consecutive days and showing an 18.59% decrease during this period. The stock's performance has been volatile, trading below key moving averages and significantly underperforming its sector, with a 25.08% decline over the past month.

Gujarat Themis Biosyn experienced notable activity on February 6, 2025, with a significant gain, outperforming its sector. The stock has shown a consistent upward trend over three days, despite facing challenges over the past month. Its performance reflects volatility within the pharmaceuticals and drugs industry.

Gujarat Themis Biosyn, a small-cap pharmaceutical company, recently experienced an evaluation adjustment amid challenging financial results for Q2 FY24-25. Key metrics, including profit before tax and net sales, showed declines, while the company maintained a strong return on equity and low debt-to-equity ratio, despite elevated stock valuation.

Gujarat Themis Biosyn, a small-cap pharmaceutical company, has faced notable declines, continuing a two-day losing streak with a total drop of 15.11%. The stock exhibited significant intraday volatility, trading between Rs 268 and Rs 305, while underperforming its sector and remaining below key moving averages.

Gujarat Themis Biosyn, a small-cap pharmaceutical company, saw its shares fall significantly today, underperforming the sector. The stock is trading below key moving averages, indicating a bearish trend. Over the past month, it has declined more than the Sensex, reflecting ongoing challenges in the market.

Gujarat Themis Biosyn, a small-cap pharmaceutical company, has encountered significant stock challenges, declining 7.12% today and underperforming its sector. The stock has shown volatility, trading below key moving averages, and has decreased 8.21% over the past month, contrasting with the broader market's smaller declines.

Gujarat Themis Biosyn, a smallcap pharmaceutical company, saw a 7.0% increase in its stock price on November 19, 2024. This gain was higher than the sector average by 6.85%, indicating a strong performance. The stock has been on a consecutive rise for the past three days, with a total gain of 11.18%. Its moving averages are currently higher than the 5-day, 20-day, and 200-day averages, but lower than the 50-day and 100-day averages. The company has outperformed the market in the past 1 day and 1 month, showing potential for growth. Investors should conduct their own research before investing.

The company's stock has recently seen a decline of -8.27%, underperforming the sector by -5.09%. The stock has been on a downward trend for the past three days, with a consecutive fall of -8.7% returns. However, it is still performing better than the 200-day moving average but lower than the 5-day, 20-day, 50-day, and 100-day moving averages. In comparison to the overall market, the stock has underperformed in the past month and on the day of the decline.

Gujarat Themis Biosyn, a smallcap pharmaceutical company, has seen a -9.8% drop in its stock price on November 7th, 2024. Despite being higher than its moving averages, the stock has underperformed the sector and the overall market, showing a trend reversal after two days of gains and high volatility.

On November 5th, 2024, Gujarat Themis Biosyn, a smallcap pharmaceutical company, saw a 9.49% increase in its stock price, outperforming the sector by 7.93%. According to MarketsMOJO, the current call for the stock is 'Hold' based on its performance and market trends. The stock has also outperformed the Sensex in the past day and month, indicating a positive trend in the short term.

On November 1st, 2024, Gujarat Themis Biosyn, a smallcap pharmaceutical company, saw a positive trend in its stock performance, gaining 8.25% and outperforming the sector by 7.99%. This marks the second consecutive day of gains, with a total increase of 8.69% in the past two days. The stock is currently trading below its moving averages, but has been given a 'Hold' call by MarketsMOJO. Despite the overall market's negative performance, Gujarat Themis Biosyn has outperformed the Sensex by 8.59% in the past day and -18.12% in the past month.

Gujarat Themis Biosyn, a smallcap pharmaceutical company, reported negative financial results for the quarter ending September 2024. The company's PBT and PAT have decreased by 20.1% and 22.7% respectively, while net sales and PBDIT have also seen a decline. EPS has reached its lowest in the last five quarters, indicating a negative trend. Investors should carefully consider these results before making any investment decisions.

Gujarat Themis Biosyn, a smallcap pharmaceutical company, has seen a decline in its stock performance on October 22, 2024, with a consecutive fall of -15.96% in the past 8 days. The stock has also shown high volatility and is currently higher than the 200 day moving average, but lower than other moving averages. In comparison to the Sensex, the company's performance has been lower in both 1 day and 1 month periods. Investors are advised to conduct their own research before investing.

Gujarat Themis Biosyn, a smallcap pharmaceutical company, has reached a 52-week high on September 25th, 2024, with a current price of Rs. 390. The stock has shown consecutive gains in the last 4 days, outperforming the sector by 1.12%. It is currently trading above its moving averages and has shown a remarkable growth of 225.86% in the past year, making it a promising company in the pharmaceutical industry. MarketsMOJO has given a 'Hold' call for the stock, suggesting investors to monitor its performance.

Gujarat Themis Biosyn, a smallcap pharmaceutical company, has reached an all-time high stock price on September 25th, 2024. Despite a slight decrease today, the stock has been on an upward trend and is currently trading higher than its moving averages. With a 225.09% increase in the past year, the company shows strong potential for future growth.